HC Wainwright & Co. Reiterates Buy on Inozyme Pharma, Maintains $14 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Inozyme Pharma (NASDAQ:INZY) and maintained a price target of $14, indicating confidence in the company's future performance.
October 25, 2024 | 10:51 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Inozyme Pharma and maintained a $14 price target, suggesting positive expectations for the company's stock performance.
The reiteration of a Buy rating and maintenance of a $14 price target by HC Wainwright & Co. suggests that the analyst has a positive outlook on Inozyme Pharma's future performance. This could lead to increased investor confidence and potentially a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100